Market Research Reports and Industry Reports

Heart Transplant Rejection - Pipeline Review, H2 2017

  • DESCRIPTION
  • TABLE OF
    CONTENTS
  • RELATED
    REPORTS
  • SAMPLE REQUEST
  • REVIEWS

Heart Transplant Rejection - Pipeline Review, H2 2017

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Heart Transplant Rejection - Pipeline Review, H2 2017, provides an overview of the Heart Transplant Rejection (Immunology) pipeline landscape.

Heart transplantation is the therapy used in various heart diseases. Heart transplant replaces an injured or diseased heart with a healthy one. Risk factors associated with transplantation are bleeding, infection, clots, and cardiovascular disorders. Following a transplant, the immune system may consider the transplanted heart as foreign and may work against it. Patients may hence develop complications and eventually reject the new organ. Immunosuppressive drugs are administered simultaneously which prevent the body from either identifying or attacking the foreign organ via various immune responses thus blocking organ rejection and facilitating a successful transplant.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Heart Transplant Rejection - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Heart Transplant Rejection (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Heart Transplant Rejection (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Heart Transplant Rejection and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration and Preclinical stages are 1 and 8 respectively.

Heart Transplant Rejection (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Heart Transplant Rejection (Immunology).
- The pipeline guide reviews pipeline therapeutics for Heart Transplant Rejection (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Heart Transplant Rejection (Immunology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Heart Transplant Rejection (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Heart Transplant Rejection (Immunology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Heart Transplant Rejection (Immunology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Heart Transplant Rejection (Immunology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and Scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Heart Transplant Rejection - Overview
Heart Transplant Rejection - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Heart Transplant Rejection - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Heart Transplant Rejection - Companies Involved in Therapeutics Development
Astellas Pharma Inc
Heat Biologics Inc
Noxxon Pharma AG
TxCell SA
Heart Transplant Rejection - Drug Profiles
2C-10 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AS-2521780 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AS-2553627 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
emapticap pegol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ENTX-MS - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclonal Antibody to Inhibit TIRC-7 for Cardiac and Kidney Transplantation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PTX-15 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit JAK3 for Heart Transplantation - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
tacrolimus - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Heart Transplant Rejection - Dormant Projects
Heart Transplant Rejection - Product Development Milestones
Featured News & Press Releases
Sep 27, 2017: Pelican Therapeutics Announces Manufacturing Agreement with KBI Biopharma to Advance PTX-15 Fusion Protein
Jun 23, 2008: Astellas submit an sNDA for the immunosuppressant Prograf for Ulcerative Colitis in Japan
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer


List Of Tables


Number of Products under Development for Heart Transplant Rejection, H2 2017
Number of Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Heart Transplant Rejection - Pipeline by Astellas Pharma Inc, H2 2017
Heart Transplant Rejection - Pipeline by Heat Biologics Inc, H2 2017
Heart Transplant Rejection - Pipeline by Noxxon Pharma AG, H2 2017
Heart Transplant Rejection - Pipeline by TxCell SA, H2 2017
Heart Transplant Rejection - Dormant Projects, H2 2017


List Of Figures


Number of Products under Development for Heart Transplant Rejection, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products by Targets, H2 2017
Number of Products by Stage and Targets, H2 2017
Number of Products by Mechanism of Actions, H2 2017
Number of Products by Stage and Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017


Global Heartbeat Sensor Sales Market Report 2017

In this report, the global Heartbeat Sensor market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing

USD 4000View Report

EMEA (Europe, Middle East and Africa) Foetal Heart Monitor Market Report 2017

In this report, the EMEA Foetal Heart Monitor market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022,

USD 4000View Report

Asia-Pacific Kidney Transplant Rejection Therapeutics Market Report 2017

In this report, the Asia-Pacific Kidney Transplant Rejection Therapeutics market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of

USD 4000View Report

Global Kidney Transplant Rejection Therapeutics Market Professional Survey Report 2017

This report studies Kidney Transplant Rejection Therapeutics in Global market, especially in North America, China, Europe, Southeast Asia, Japan and India, with production, revenue, consumption, import and export in these

USD 3500View Report

Fill The Form For Sample Request
Full Name :*
Bussiness Email: *
Email: *
Country :*
Contact No.*
Alternate No.
Note.:*Kindly provide us with your company id and get the sample reports at the earliest.
There is no Reviews available

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    USD 2000
  • Site Licence    USD 4000
  • Enterprise Wide Licence    USD 6000
$ 2000

Reports Details

Published Date : Dec 2017
No. of Pages :33
Country :Global
Category :Pharmaceuticals and Healthcare
Publisher :Global Markets Direct
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

payment
  • fb
  • twitter
  • pinterest
  • linckedin
  • rss
  • youtube